trending Market Intelligence /marketintelligence/en/news-insights/trending/mw7A5Yuv68Etj3nA7iOfOA2 content esgSubNav
In This List

Biotricity's remote heart disease monitoring device secures US FDA clearance

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Biotricity's remote heart disease monitoring device secures US FDA clearance

The U.S. Food and Drug Administration granted 510(k) clearance to Biotricity Inc.'s Bioflux device.

Bioflux consists of a proprietary mobile electrocardiography or ECG monitoring device and an ECG viewer software package that enables physicians to remotely monitor and diagnose patients with cardiovascular coronary heart disease.